These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22433961)

  • 1. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females.
    Li R; Li Y; Radley D; Liu Y; Huang T; Sings HL; Zhang L; Wang W; Zhong X; Saah AJ
    Vaccine; 2012 Jun; 30(28):4284-91. PubMed ID: 22433961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
    Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
    Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
    Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
    Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
    Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
    Li J; Shi LW; Yu BW; Huang LR; Zhou LY; Shi L; Jiang ZW; Xia JL; Wang XY; Li RC; Yuan L; Li YP; Li CG
    Vaccine; 2023 May; 41(19):3141-3149. PubMed ID: 37061370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects.
    Kang S; Kim KH; Kim YT; Kim YT; Kim JH; Song YS; Shin SH; Ryu HS; Han JW; Kang JH; Park SY
    Int J Gynecol Cancer; 2008; 18(5):1013-9. PubMed ID: 17986242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
    Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
    J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.